Spotlight on adapalene Adapalene Pirard, Pirard-Franchimont, Paquet & Quatresooz

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1565-1575

  Piérard, Gérald E ^a   Pirard Franchimont, Claudine ^a   Paquet, P ^a   Quatresooz, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acne; Adapalene; Comedolysis; Naphthoic acid; Retinoic acid; Retinoid; Tazarotene

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN; DOXYCYCLINE; EPIDUO; LYMECYCLINE; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; MEDICAL PRACTICE; NONHUMAN; PRURITUS; REVIEW; ROSACEA; SKIN DISEASE; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW; XEROSIS; ACNE; ANIMAL; CLINICAL TRIAL;

ACNEIFORM ERUPTIONS; ANIMALS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; HUMANS; NAPHTHALENES; SKIN DISEASES;

EID: 71049157949     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903386269     Document Type: Review

References (107)

1. Piérard-Franchimont C, Henry F, Fraiture AL, et al. Split-face clinical and bio-instrumental comparison of 0.1 % adapalene and 0.05 % tretinoin in facial acne. Dermatology 1999;198:218-222
2. Uhoda E, Piérard-Franchimont C, Petit L, et al. The conundrum of skin pores in dermocosmetology. Dermatology 2005;210:3-7
3. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2001;121:20-27
4. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: Update on efficacy and safety. Am J Clin Dermatol 2008;9:369-381
5. Kang S. The mechanism of action of topical retinoids. Cutis 2005;75:S10-3
6. Bikowski JB. Mechanisms of the cormedolytic and anti-inflamamtory properties of topical retinoids. J Drugs Dermatol 2005;4:41-47
7. Chytil F. Retinoic acid: Biochemistry, pharmacology, toxicology and therapeutic use. Pharmacol Rev 1984;36:S93-100
8. Simoni D, Tolomeo M. Retinoids, apoptosis and cancer. Curr Pharam Des 2001;7:1823-1837
9. Darmon M, Rocher M, Cavey MT, et al. Biological activity of retinoids correlates with affinity for nuclear receptors but not for cytosolic binding protein. Skin Pharmacol 1988;1:161-175
10. Asselineau D, Cavey MT, Shroot B, Darmon M. Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP). J Invest Dermatol 1992;98:128-134
11. Elder JT, Aström A, Pttersson U, et al. Retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992;98:S36-41
12. Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol 2005;6:13-19
13. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000;6:919-931
14. Leyden JJ, Shalita A, Thiboutot D, et al. Topical retinoids in inflammatory acne: A retrospective, investigator-blinded, vehicle-controlled. photographic assessment. Clin Ther 2005;27:216-224
15. Cunliffe WJ. European multicentre study of adapalene versus tretinoin gel. Br J Dermatol 1996;135:S29-30
16. Chen M, Goyal S, Cai X, et al. Modulation of type VII collagen (anchoring fibril) expression by retinoids in human skin cells. Biochim Biophys Acta 1997;1351:333-340
17. Varani J, Warner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol 2000;114:480-486
18. Piérard GE, Henry F, Piérard-Franchimont C. Comparative effect of short-term topical tretinoin and glycolic acid on mechanical properties of photodamaged facial skin in HRT-treated menopausal women. Maturitas 1996;23:273-277
19. Jetten AM, Anderson K, Deas MA, et al. New benzoic acid derivatives with retinoid activity: Lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res 1987;47:3523-3527
20. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998;139:S8-10
21. Chen S, Ostrowski J, Whiting G, et al. Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models. J Invest Dermatol 1995;104:779-783
22. Sakuta T, Kanayama T. Comedolytic effect of a novel RAR gamma-specific retinoid, ER36009: Comparison with retinoic acid in the rhino mouse model. Eur J Dermatol 2005;15:459-464
23. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol 1993;6:S61-9
24. Brogden RN, Goa KL. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997;53:511-519
25. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997;36:S96-103
26. Griffiths CE, Elder JT, Bernard BA, et al. Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: Dissociation of epidermal effects and CRABP-II mRNA expression. J Invest Dermatol 1993;101:325-328
27. Bernerd F, Ortonne JP, Bouclier M, et al. The rhino mouse model: The effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utricle wall of pseudocomedones. Arch Dermatol Res 1991;283:100-107
28. Bouclier M, Chatelus A, Ferracin J, et al. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol 1991;4:65-73
29. Jamoulle JC, Grandjean L, Lamaud E, et al. Follicular penetration and distribution of topically applied CD271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol 1990;94:731-732
30. Schaefer H, Watts F, Brod J, et al. Follicular penetration. In: Scott RC, Guy RH, Hadgraft J, editors, Prediction of percutaneous penetration, methods, measurements, modelling. London, IBC Technical Services; 1990. p. 163-173
31. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997;36:S119-25
32. Brenna E, Frigoli S, Fronza G, et al. Isolation and characterization of impurities in adapalene. J Pharm Biomed Anal 2007;43:1161-1163
33. Trichard L, Delgado-Charro MB, Guy RH, et al. Novel beads made of alpha-cyclodextrin and oil for topical delivery of a lipophilic drug. Pharm Res 2008;25:435-440
34. Waugh J, Noble S, Scott LJ. Adapalene: A review of its use in the treatment of acne vulgaris. Drugs 2004;64:1465-1478
35. Campbell JL, Weiss JS. The results of the MORE trial: Overview. Cutis 2006;78:S5-11
36. Gold LS. The MORE trial: Effectiveness of adapalene gel 0.1% in real-world dermatology practices. Cutis 2006;78:S12-8
37. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel 0.1% as maintenance therapy for acne vulgaris: A randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;142:597-602
38. Alirezai M, George SA, Coutts I, et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007;17:45-51
39. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel 0.1%. J Eur Acad Dermatol Venereol 2007;21:747-753
40. Irby CE, Yentzer BA, Feldman SR. A review of adapalene in the treatment of acne vulgaris. J Adolesc Health 2008;43:421-424
41. Kawahsima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris : A randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci 2008;49:241-248
42. Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: Clinical evidence for adapalene 0.1% in combination therapies. J Drugs Dermatol 2006;5:785-794
43. Lucky A, Jorizzo JL, Rodriguez D, et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001;68:S34-40
44. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials. Br J Dermatol 1998;139:S48-56
45. Bikowski J. A new approach to comparing efficacy results from clinical trials of topical acne vulgaris treatments. J Drugs Dermatol 2007;6:688-692
46. Czernielewski J, Poncet M, Mizzi F. Efficacy and cutaneous safety of adapalene in Black patients versus White patients with acne vulgaris. Cutis 2002;70:243-248
47. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol 2001;15:S37-42
48. Tu P, Li GQ, Zhu XJ, et al. A comparison of adapalene gel 0.1% vs tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol 2001;15:S31-6
49. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial. J Am Acad Dermatol 1996;34:482-485
50. Caron D, Sorba V, Kerrouche N, Clucas A. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% in acne patients. J Am Acad Dermatol 1997;36:S110-2
51. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997;26:S126-34 (Pubitemid 27265894)
52. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials. Br J Dermatol 1998;139:S48-56
53. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: Its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998;139:S17-22
54. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998;139:S34-40
55. Thiboutot D, Gold MH, Jarratt MT, et al. Randomised controlled trial of the tolerability, safety and efficacy of adapalene gel 01% and tretinoin microsphere gel 01% for the treatment of acne vulgaris. Cutis 2001;68:S10-9
56. Cunliffe WJ, Danby FW, Dunlap F, et al. Randomised, controlled trial of the efficacy and safety of adapalene gel 01% and tretinoin cream 005% in patients with acne vulgaris. Eur J Dermatol 2002;12:350-354
57. Jain S. Topical tretinoin or adapalene in acne vulgaris: An overview. J Dermatol Treat 2004;15:200-207
58. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris : A muticenter, double-blind, randomized, parallel-group study. J Drugs Dermatol 2005;4:153-158
59. Pariser D, Colon LE, Johnson LA, Gottschalk RW. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drugs Dermatol 2008;7:S18-23
60. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol 2008;7:S3-S10
61. Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 01% and vehicle. Cutis 2005;76:145-151
62. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006;54:242-250
63. Weiss JS, Thiboutot DM, Hwa J, et al. Long-term safety and efficacy study of adapalene 0.3% gel. J Drugs Dermatol 2008;7:S24-8
64. Alirezai M, Meynadier J, Jablonska S, et al. Comparative study of the efficacy and tolerability of 0.1 and 0.03% adapalene gel and 0.025% tretinoin gel in the treatment of acne. Ann Dermatol Venereol 1996;123:165-170
65. Korkut C, Piskin S. Benzoyl peroxide, adapalene and their combination in the treatment of acne vulgaris. J Dermatol 2005;32:169-173
66. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed- dose combination for the treatment of acne vulgaris: results of a mutlicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007;57:791-799
67. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol 2007;6:899-905.
68. Loesche C, Pernin C, Poncet M. Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol 2008;18:524-526
69. Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris : A transatlantic, randomized, double-blind controlled study in 1670 patients. Br J Dermatol 2009. [Epub May 21]
70. Ko HC, Song M, Seo SH, et al. Prospective, open-label, comparative study of clindamycin 1% benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients : Efficacy and tolerability. J Eur Acad Dermatol Venereol 2009;23:245-250
71. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007;6:616-622
72. Webster G. Mechanism-based treatment of acne vulgaris: The value of combination therapy. J Drugs Dermatol 2005;4:281-288
73. Del Rosso JQ. Combination topical therapy in the treatment of acne. Cutis 2006;78:S5-12
74. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: A mutlicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49:S211-7
75. Zhang JZ, Li LF, Tu YT, et al. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatol Treat 2004;15:372-378
76. Cunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 01%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003;49:S218-26
77. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: A multicenter, investigator-blind, randomized, controlled study. Skin Med 2005;4:138-146
78. Cassano N, Amoruso A, Alessandrini G, et al. Treatment of inflammatory acne with a combination therapy with lymecycline and adapalene followed by maintenance treatment with adapalene. Eur J Inflam 2004;2:45-52
79. Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet 1997;350:339
80. Givre SJ, Fleischman D. Intracranial hypertension in a patient using topical adapalene. J Neuroophthalmol 2008;28:156-158
81. Birth defects due to topical adapalene tretinoin. Prescrire Int 1998;7:148-149
82. Caron D, Sorba V, Clucas A, Verschoore M. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol 1997;36:S113-5
83. Verschoore M, Poncet M, Czernielewski J, et al. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 1997;36:S104-9
84. Stinco G, Bragadin G, Trotter D, et al. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol 2007;21:320-325
85. Dunlap FE, Mills OH, Ruley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: Its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998;149:S17-22
86. Toole JW, Lockhart L, Potrebka J, et al. Comparative irritancy study among retinoid creams and gels. J Cutan Med Surg 1999;3:298-301
87. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis 2003;72:76-81
88. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis 2005;75:238-243 (Pubitemid 40627632)
89. Leyden JJ, Grossman R, Nighland M. Cumulative irritation potential of topical retinoid formulations. J Drugs Dermatol 2008;7:S14-8
90. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis 2005;75:289-293 (Pubitemid 40826409)
91. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003;49:S227-32
92. Caron D, Sorba V, Clucas A, et al. Skin tolerance of adapalene 0.1% gel in combination with other topical anti-acne treatments. J Am Acad Dermatol 1997;36:S113-5
93. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003;49:S227-32
94. Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol 2009;8:383-388
95. Dosik JS, Gilbert RD, Arsonnaud S. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skin Med 2006;5:219-223
96. Queille-Roussel C, Poncet M, Mecaros S, et al. Comparison of the cumulative irritation potential of adapalene gel and adapalene solution (0.1%) with tazarotene gel and several tretinoin formulations. Clin Ther 2001;23:205-212
97. Bouclier M, Luginbuhl B, Shroot B, Hensby CN. Arachidonic acid induced ear oedema in four strains of rats and mice: A comparative study of anti-inflammatory drugs. Agents Actions 1990;29:62-64
98. Wolf JE. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther 2002;19:109-118
99. Akdeniz N, Calka O, Ozbek H, Metin A. Anti-inflammatory effects of tretinoin (all-trans-retinoic acid) 0.1% and adapalene 0.1% in rats. Clin Exp Dermatol 2005;30:570-572
100. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007;16:500-506
101. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: All-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005;174:2467-2470
102. Altinyazar HC, Koca R, Tekin NS, Estürk E. Adapalene vs metronidazole gel for the treatment of rosacea. Int J Dermatol 2005;44:252-255
103. Dogra S, Kanwar AJ. Milia en plaque. J Eur Acad Dermatol Venereol 2005;19:263-264
104. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007;56:500-505
105. Casals M, Campoy A, Aspiolea F, et al. Successful treatment of linear Darier's disease with topical adapalene. J Eur Acad Dermatol Venereol 2009;23:237-238
106. Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol 2006;54:S262-71
107. Disilvestro PA, Disilvestro JM, Lernhardt W, et al. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J Low Genit Tract Dis 2001;5:33-37